Clinical Trial of Sirolimus balloon catheter: Cardiologist invests 60 million dollar in Device maker

Published On 2018-10-13 07:00 GMT   |   Update On 2018-10-13 07:00 GMT

HOUSTON: An Indian-American cardiologist and entrepreneur has invested $60 million in a medical company that will support clinical trial on cardiac devices to replace the stent.


Dr Kiran Patel's investment is for the Concept Medical Inc, a Florida-based medical device company's Investigational Device Exemption (IDE) for the world's first sirolimus-coated balloon.

Sirolimus balloon catheter is a drug-coated balloon, which is a replacement of the stent. If a stent cannot be placed in the human body or doesn't have a good outcome, then sirolimus balloon is used.

According to the company, the investment by the Indian American cardiologist will pave way for clinical studies to reduce the risk of heart blockages.

Patel's investment will pay for clinical studies on cardiac devices coated with a substance that reduces the risk of heart blockages and the length of time a patient needs to take blood thinners, according to a statement issued by the company.

Noting that cardiovascular diseases represent 31 per cent of all global deaths, Patel said that his contribution will help towards the healthcare of millions of people around the world.

"I am excited to be a part of CMI whose research & innovative technologies will meet a major unmet need in patients with diabetes and cardiovascular diseases. This venture enables me to contribute to the millions of hearts beating around the world," Patel was quoted as saying in the release.

A portion of the funds will also be utilised to bolster the manufacturing operations to meet the increasing demand for their products globally.
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News